Zevra Therapeutics, Inc. ZVRA 深 沪
等待开盘 06-25 09:30:00 美东时间
13.08
+0.080
+0.62%
华盛通- 最 高13.315
- 今 开13.00
- 成交量 98.47万股
- 最 低 12.932
- 昨 收 13.00
- 总市值 7.73亿
- 52周最高 14.27
- 市盈率 静 9.65
- 换手率 1.67%
- 52周最低 7.16
- 委 比 -76.24%
- 总股本 5911.51万
- 历史最高 418.40
- 量 比 0.70
- 振 幅 2.95%
- 历史最低 0.206
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced the publication of "Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label ...
06-23 19:36
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Zevra Therapeutics Submits U.S. Patent For MIPLYFFA To FDA For Listing In Orange Book Publication; Patent Expires On November 19, 2041
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041Separately filed patent term extension remains pending with the U.S. Patent and Trademark OfficeBOSTON, June 08, 2026 (GLOBE NEWSWIRE)
06-08 19:34
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.
05-08 21:29
Zevra Therapeutics shares are trading lower. The company reported its Q1 financial results.
Zevra Therapeutics shares are trading lower. The company reported its Q1 financ...
05-08 00:50
CORRECTION: Zevra Therapeutics Q1 Adj. EPS $0.18 Beats $0.08 Estimate, Sales $36.220M Beat $31.960M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.08 by 125 percent. This is a 400 percent increase over losses of $(0.06) per share from the
05-07 05:23
